We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > VAL-083

News List

Kintara, GCAR Execute Agreement for VAL-083's Participation in the GBM AGILE Study americanpharmaceuticalreview
October 28, 2020
Kintara Therapeutics announced the execution of an agreement with the Global Coalition for Adaptive Research (GCAR) for VAL-083's participation in GCAR's Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) Study.
DelMar Updates Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors americanpharmaceuticalreview
May 07, 2020
DelMar Pharmaceuticals has enrolled 22 patients in the adjuvant arm of the Company's ongoing Phase 2 clinical study investigating adjuvant treatment (pre-temozolomide -- or TMZ -- maintenance therapy) of MGMT-unmethylated glioblastoma multiforme (GBM) ...
DelMar Pharmaceuticals Relocates Headquarters to San Diego americanpharmaceuticalreview
September 09, 2019
DelMar Pharmaceuticals announced the Company has relocated its headquarters from Vancouver, British Columbia to San Diego, California.